Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: Model-based analysis of clinical data

American Journal of Physiology - Renal Physiology

Volumn 315, Issue 5, 2018, Pages F1295-F1306

  Hallow, K Melissa ^a,b   Greasley, Peter J ^d   Helmlinger, Gabriel ^c   Chu, Lulu ^c   Heerspink, Hiddo J ^e   Boulton, David W ^c  

^a University of Georgia   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Computational modeling; Heart failure; Renal function; SGLT2 inhibition

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 1;

ADULT; ARTICLE; BLOOD VOLUME; CLINICAL OBSERVATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIURESIS; DRUG MECHANISM; EVALUATION STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; INTERSTITIAL FLUID; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; OSMOTIC DIURESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SODIUM URINE LEVEL; BIOLOGICAL MODEL; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; COMPUTER SIMULATION; DRUG EFFECT; HEART FAILURE; HEMODYNAMICS; KIDNEY; KIDNEY TUBULE ABSORPTION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR SYSTEM; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DIURESIS; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEART FAILURE; HEMODYNAMICS; HUMANS; KIDNEY; MODELS, CARDIOVASCULAR; RENAL INSUFFICIENCY, CHRONIC; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85055484712     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00202.2018     Document Type: Article

References (44)

1. Anderson S, Brenner BM. The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens Suppl 4: S236 – S238, 1986.
2. Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul Integr Comp Physiol 303: R1101–R1109, 2012. doi:10.1152/ajpregu.00390.2012.
3. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17: 1180 –1193, 2015. doi:10.1111/dom.12572.
4. Coady MJ, El Tarazi A, Santer R, Bissonnette P, Sasseville LJ, Calado J, Lussier Y, Dumayne C, Bichet DG, Lapointe JY. MAP17 is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol 28: 85–93, 2017. doi:10.1681/ASN.2015111282.
5. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169 –3176, 2013. doi:10.2337/dc13-0387.
6. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39: 1108 –1114, 2016. doi:10.2337/dc16-0330.
7. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J 39: 363–370, 2018. doi:10.1093/eurheartj/ehx511.
8. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37: 1526 –1534, 2016. doi:10.1093/eurheartj/ehv728.
9. Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration (Abstract). Diabetes 63: A132, 2014.
10. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187– 196, 2012. doi:10.2337/db11-1029.
11. Hallow KM, Gebremichael Y. A quantitative systems physiology model of renal function and blood pressure regulation: application in salt-sensitive hypertension. CPT Pharmacometrics Syst Pharmacol 6: 393– 400, 2017. doi:10.1002/psp4.12177.
12. Hallow KM, Gebremichael Y. A quantitative systems physiology model of renal function and blood pressure regulation: model description. CPT Pharmacometrics Syst Pharmacol 6: 383–392, 2017. doi:10.1002/psp4. 12178.
13. Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregu-lation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol 312: F819 –F835, 2017. doi:10.1152/ajprenal.00497.2016.
14. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJ, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20: 479 –487, 2018. doi:10.1111/dom.13126.
15. 23Na magnetic resonance imaging of the lower leg of acute heart failure patients during diuretic treatment. PLoS One 10: e0141336, 2015. doi:10.1371/journal. pone.0141336.
16. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 8: 293–300, 2012. doi:10.1038/nrneph.2012.19.
17. Irsik DL, Blazer-Yost BL, Staruschenko A, Brands MW. The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses. Am J Physiol Regul Integr Comp Physiol 312: R965–R972, 2017. doi:10.1152/ajpregu.00354.2016.
18. Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol 17: 5, 2018. doi:10. 1186/s12933-017-0654-z.
19. Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 76: 432–444, 2013. doi:10.1111/bcp.12056.
20. 23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension 61: 635–640, 2013. doi:10.1161/HYPERTENSIONAHA.111.00566.
21. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853–862, 2013. doi:10.1111/dom.12127.
22. Layton AT, Vallon V. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol 314: F969 –F984, 2018. doi:10.1152/ajprenal.00551.2017.
23. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644 –657, 2017. doi:10.1056/NEJMoa1611925.
24. Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens 25: 50 –58, 2016. doi:10.1097/MNH.0000000000000187.
25. + exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25: 2028 –2039, 2014. doi:10.1681/ASN.2013060588.
26. Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol 16: 29, 2017. doi:10. 1186/s12933-017-0511-0.
27. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188 –F193, 2014. doi:10.1152/ajprenal.00518.2013.
28. Sarashina A, Ueki K, Sasaki T, Tanaka Y, Koiwai K, Sakamoto W, Woerle HJ, Salsali A, Broedl UC, Macha S. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther 36: 1606 –1615, 2014. doi:10.1016/j. clinthera.2014.08.001.
29. Schneider MP, Raff U, Kopp C, Scheppach JB, Toncar S, Wanner C, Schlieper G, Saritas T, Floege J, Schmid M, Birukov A, Dahlmann A, Linz P, Janka R, Uder M, Schmieder RE, Titze JM, Eckardt KU. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol 28: 1867–1876, 2017. doi:10.1681/ASN.2016060662.
30. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 113: 155–159, 1990. doi:10.7326/0003-4819-113-2-155.
31. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 18: 2028 –2031, 2007. doi:10. 1681/ASN.2006111302.
32. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 46: 396 –404, 1994. doi:10. 1038/ki.1994.287.
33. Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 16: 138, 2017. doi:10.1186/s12933-017-0621-8.
34. Titze J. Sodium balance is not just a renal affair. Curr Opin Nephrol Hypertens 23: 101–105, 2014. doi:10.1097/01.mnh.0000441151.55320.c3.
35. Titze J. Water-free sodium accumulation. Semin Dial 22: 253–255, 2009. doi:10.1111/j.1525-139X.2009.00569.x.
36. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009 –R1022, 2011. doi:10.1152/ajpregu.00809.2010.
37. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104 –112, 2011. doi:10.1681/ASN. 2010030246.
38. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74: 351–375, 2012. doi:10.1146/annurev-physiol-020911-153333.
39. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60: 215–225, 2017. doi:10.1007/s00125-016-4157-3.
40. Wang W, Hallow KM, James DA. A tutorial on RxODE: simulating differential equation pharmacometric models in R. CPT Pharmacometrics Syst Pharmacol 5: 3–10, 2016. doi:10.1002/psp4.12052.
41. Wanner C. EMPA-REG OUTCOME: the nephrologist’s point of view. Am J Med 130, 6 Suppl: S63–S72, 2017. doi:10.1016/j.amjmed.2017.04. 007.
42. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016. doi:10.1056/NEJMoa1515920.
43. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George JT, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation 137: 119 –129, 2018. doi:10.1161/CIRCULATIONAHA.117.028268.
44. Wiig H, Luft FC, Titze JM. The interstitium conducts extrarenal storage of sodium and represents a third compartment essential for extracellular volume and blood pressure homeostasis. Acta Physiol (Oxf) 222: e13006, 2018. doi:10.1111/apha.13006.